« Back
Home /
Y-27632

Y-27632

Item no.	HY-10071-10mM
Manufacturer	MedChem Express
CASRN	146986-50-7
Amount	10 mMx1 mL
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 200 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.91
Citations	[1]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. [2]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332-5. [3]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51. [4]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36. [5]Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17(2):222-227. [6]Kan L, et al. Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells. PLoS One. 2015;10(12):e0144513. Published 2015 Dec 8. [7]Zhang L, et al. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One. 2011;6(3):e18271. Published 2011 Mar 28. [8]Svoboda KK, et al. ROCK inhibitor (Y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn. 2004;229(3):579-590. ACS Appl Mater Interfaces. 2022 May 11. Acs Biomater Sci Eng. 2022 Mar 1. Acs Biomater Sci Eng. 2023 Jan 20. Acta Neuropathol Commun. 2024 Sep 14;12(1):150. Acta Pharm Sin B. 2023 May 16. Adv Healthc Mater. 2021 Feb 15;e2002103. Adv Mater Interfaces. 2024 Sep 03. Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. Adv Sci (Weinh). 2023 Nov 29:e2303088. Adv Sci (Weinh). 2024 May 20:e2307216. Adv Ther. 2024 April 30. Adv Ther. 2024 Jul 18. Anal Chem. 2017 Oct 17;89(20):10841-10849. Ann Surg Oncol. 2024 Jan 4. Bioact Mater. 14 August 2022. Bioact Mater. 2021 Jun 1. Bioact Mater. 2023 Aug. Bioact Mater. 2024 Jun 14:40:244-260. Biochem Biophys Rep. September 2022, 101299. Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577. Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140. Biochem Biophys Res Commun. 2023 Bioengineered. 2022 Apr;13(4):8747-8758. Bioengineering (Basel). 2020 Dec 18;7(4):164. Biology (Basel). 2023, 12(6), 888. Biomater Adv. 2023 Dec 26, 213751. Biomaterials. 2020 May;240:119849. Biomaterials. 2020 Nov;258:120284. Biomaterials. 2024 Jan 1:305:122462. Biomed Pharmacother. September 2022, 113465. Biomed Res Int. 2021 May 15. bioRxiv. 2020 Aug. bioRxiv. 2020 Mar. bioRxiv. 2023 Dec 6. bioRxiv. 2023 Feb 24. bioRxiv. 2023 Jul 1. bioRxiv. 2023 Jun 22. bioRxiv. 2023 Jun 28. bioRxiv. 2023 Mar 1. bioRxiv. 2024 Aug 12:2024.08.12.607571. bioRxiv. 2024 Feb 18. bioRxiv. 2024 September 07. bioRxiv. January 16, 2022. Biosci Biotechnol Biochem. 2021 Jul 23;zbab136. BMC Cancer. 2023 Jun 22;23(1):577. BMC Pulm Med. 2023 Dec 13;23(1):505. BMC Urol. 2021 Jan 6;21(1):5. Bone Res. 2022 Jan 3;10(1):1. Brain Res. 15 December 2021, 147684. Can Respir J. 10 Oct 2022. Cancer Cell Int. 2024 Jul 25;24(1):263. Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12. Cancer Cell. 2024 Jun 10;42(6):1086-1105.e13. Cancer Lett. 2019 Apr 28;448:117-127. Cancer Res. 2022 Dec 8;CAN-22-2370. Cancers (Basel). 2021, 13(13), 3282. Cell Biochem Biophys. 2023 Oct 6. Cell Biosci. 2024 May 22;14(1):65. Cell Death Dis. 2022 Aug 24;13(8):730. Cell Death Dis. 2023 Apr 20;14(4):280. Cell Death Dis. 2024 Aug 3;15(8):559. Cell Death Discov. 2023 Jan 25;9(1):32. Cell Discov. 2021 Apr 19;7(1):25. Cell Discov. 2022 Apr 19;8(1):35. Cell Prolif. 2022 Aug 3;e13320. Cell Prolif. 2022 Mar 11;e13209. Cell Prolif. 2024 Jan 12:e13599. Cell Regen. 2020 Sep 3;9(1):15. Cell Rep Med. 2023 Jan 10;100911. Cell Rep Methods. 2024 Aug 27:100843. Cell Rep Methods. 2024 May 8:100777. Cell Rep. 2023 May 2;42(5):112445. Cell Rep. 2023 Oct 5;42(10):113213. Cell Rep. 2019 Jan 8;26(2):407-414.e5. Cell Res. 2023 Jul 17. Cell Signal. 2024 May 8:111223. Cell Stem Cell. 2020 Oct 1;27(4):646-662.e7. Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10. Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. Cell. 2024 Jul 25;187(15):3936-3952.e19. Cells. 2023 Dec 30, 13(1), 81. Cells. 2024 Aug 31. Chem Biol Interact. 17 August 2021, 109625. Chem Eng J. 1 January 2023, 138737. Chem Eng J. 2024 Apr 1, 485, 149884. Circ Res. 2020 Oct 9;127(9):1182-1194. Clin Mol Hepatol. 2023 Feb 20. Compos Part B-Eng. 2023 Apr 6, 110711. Connect Tissue Res. 2022 Jan 12;1-10. Curr Med Sci. 2024 Jun 27. Device. 2024 June 12 EMBO Mol Med. 2022 Dec 13;e16373. Environ Pollut. 2020 Jun;261:114153. Environ Toxicol Pharmacol. 2023 Oct 20:104301. Eur J Cell Biol. 2024 May 28;103(2):151427. Eur J Immunol. 2022 Aug;52(8):1308-1320. Exp Mol Med. 2021 Sep 21. Exp Mol Med. 2023 Jun 19. Exp Ther Med. 2021 Feb 3. F1000Research. 03 Aug 2022. FASEB J. 03 October 2022. Front Cell Dev Biol. 2021 Jun 24;9:670825. Front Med. 2021 Sep 23;8:746298. Front Physiol. 2020 Jun 30;11:669. Gut Microbes. 2022, 14(1): 2139978. Harvard Medical School LINCS LIBRARY Hum Mol Genet. 2022 Aug 10;ddac190. Immunity. 2022 Mar 15;S1074-7613(22)00124-8. Int J Biol Sci. 2022 Aug 29;18(14):5459-5474. Int J Chron Obstruct Pulmon Dis. 2024 Jul 8:19:1591-1601. Int J Mol Med. 2024 Nov;54(5):99. Int J Mol Sci. 2022, 23(23), 14637 Int J Mol Sci. 2023 Oct 31, 24(21), 15804. Int J Mol Sci. 2024 Apr 9, 25(8), 4138. iScience. 19 October 2021, 103303. iScience. 2023 Aug 26. J Biol Chem. 2023 Oct 19:105361. J Biol Eng. 2024 Jan 16;18(1):7. J Biosci Bioeng. 2020 Dec 23;S1389-1723(20)30432-1. J Bone Oncol. October 2021, 100391. J Cancer Res Clin Oncol. 2024 Sep 19;150(9):424. J Cell Mol Med. 2020 Jul;24(14):8179-8193. J Clin Invest. 2022 Jan 25;e154993. J Clin Med. 2019 Oct 21;8(10):1751. J Immunother Cancer. 2024 Apr 19;12(4):e008628. J Med Chem. 2019 Jul 11;62(13):6083-6101. J Neuroinflammation. 2024 Apr 10;21(1):88. J Neurosci. 2021 Jan 20;41(3):392-407. J Transl Med. 2023 Oct 10;21(1):711. J Virol. 2021 Feb 24;95(10):e02436-20. J Virol. 2023 Apr 27;e0177022. JCI Insight. 2024 Apr 23:e171916. Life Sci. 2020 Apr 1;246:117419. Life. 2021, 11(8), 789. Mat Sci Eng C-Mater. 2021, 111939. Med Sci Monit. 2018 May 27;24:3514-3523. Methods Mol Biol. 2022 Dec 15. Methods Mol Biol. 2023;2683:53-68. Microsyst Nanoeng. 2024 Jul 15:10:97. Mol Cancer. 2024 Jan 10;23(1):12. Mol Cancer. 2024 Jun 8;23(1):125. Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. Mol Med. 2023 Oct 20;29(1):139. Mol Neurobiol. 2024 Mar 20. Nat Cell Biol. 2022 Jun;24(6):858-871. Nat Commun. 2022 Apr 19;13(1):2028. Nat Commun. 2022 Jun 1;13(1):3060. Nat Commun. 2022 Sep 6;13(1):5237. Nat Commun. 2023 Apr 6;14(1):1912. Nat Commun. 2023 Aug 8;14(1):4779. Nat Commun. 2024 Aug 5;15(1):6626. Nat Commun. 2024 Feb 19;15(1):1493. Nat Commun. 2024 Feb 7;15(1):1150. Nat Commun. 2024 Mar 11;15(1):2192. Nat Commun. 2024 May 30;15(1):4590. Nat Genet. 2024 Feb;56(2):294-305. Neurotherapeutics. 2021 Jan 21. NPJ Regen Med. 2022 Jun 16;7(1):31. Npj Viruses. 2024 Sep 02. Nutr Metab. 2020 Oct 26;17:91. Oncogene. 2023 Aug 31. Oncol Rep. 2020 Sep;44(3):1266-1274. Oncotarget. 2017 Jul 31;8(47):82506-82530. Patent. US20210284970A1. Patent. US20220177852A1. Patent. US20220267735A1. Patent. US20240018470A1. Pharmacol Res. 2022 Dec 16;187:106615. Phytother Res. 2024 Feb 15. Protein Cell. 2021 Feb;12(2):107-127. Reprod Toxicol. 2023 Dec 12:123:108522. Research (Wash D C). 2023 Oct 24. Research Square Preprint. 2021 Jan. Research Square Preprint. 2021 May. Research Square Preprint. 2021 Oct. Research Square Preprint. 2022 Jan. Research Square Preprint. 2022 Jun. Research Square Preprint. 2023 May 30. Respir Res. 2022 Mar 25;23(1):70. Sci Adv. 2023 Dec 22;9(51):eadi5683. Sci Adv. 2023 Oct 27;9(43):eadg6686. Sci Rep. 2017 Dec 19;7(1):17770. Sci Rep. 2021 Dec 7;11(1):23564. Sci Rep. 2019 Dec 17;9(1):19301. Sci Total Environ. 2020 Jul 10;725:138433. Sci Total Environ. 2022 May 18;838(Pt 2):155811. Small. 2021 Jun 8;e2100546. Small. 2021 Nov 2;e2104773. SSRN. 2023 Feb 6. SSRN. 2024 Jan 22. STAR Protoc. 2021 Nov 5;2(4):100881. STAR Protoc. 2023 Feb 3;4(1):102092. Stem Cell Res Ther. 2024 Oct 8;15(1):350. Stem Cell Res Ther. 2019 May 31;10(1):155. Stem Cell Res. 2021, 102157. Stem Cell Res. 2021, 102217. Stem Cell Res. 2022 Sep 15;64:102916. Stem Cell Res. 2024 Feb 3:76:103327. Stem Cell Res. 2024 Mar 24, 103399. Theranostics. 2022 Mar 21;12(6):2908-2927. Theranostics. 2022 Mar 28;12(7):3131-3149. Theranostics. 2022; 12(17): 7250-7266 Theranostics. 2023 May 27;13(10):3290-3309. Toxicology. 2020 Oct;443:152573. Vaccines. 2023 May 17, 11(5), 993. Virology. 2023 May 3;583:45-51. Virology. 2024 Dec. Am J Physiol Cell Physiol. 2023 May 1. Biochem Biophys Res Commun. 2021 Mar 18;552:142-149. Biomaterials. 2021, 120684. Biomolecules. 2023, 13(1), 69. bioRxiv. 2023 Dec 22. bioRxiv. 2023 Feb 16. bioRxiv. 2024 Feb 1. bioRxiv. 2024 Feb 27. bioRxiv. 2024 Jan 5. bioRxiv. 2024 September 14. bioRxiv. April 21, 2022. Breast Cancer Res. 2021 Aug 3;23(1):82. Cancers (Basel). 2022 May 17;14(10):2463. Cancers (Basel). 2023, 15(3), 931. cell analysis. 2020 Aug. Cell Mol Gastroenterol Hepatol. 2022 Nov 24;S2352-345X(22)00238-7. Cell Rep. 2024 Jan 9;43(1):113668. Cell Rep. 2024 Mar 1;43(3):113892. Cell Rep. 2024 May 10;43(5):114206. Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7. Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12. Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8. Cell Stem Cell. 2022 May 5;29(5):776-794.e13. Cell Stem Cell. 2022 Oct 6;29(10):1475-1490.e6. Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. Cell. 2024 Sep 18:S0092-8674(24)00977-2. Curr Protoc Cell Biol. 2018 Dec;81(1):e62. Curr Protoc. 2023 Oct;3(10):e915. Environ Pollut. 2024 Mar 8:123743. Environ Sci Technol. 2024 Apr 30. Food Chem Toxicol. 2020 Jan;135:111015. Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):1. iScience. 2022 Dec 26;26(1):105898. iScience. 2023 May 29;26(7):107001. iScience. 2024 Feb 5;27(3):109111. iScience. 2024 Jul 8;27(8):110470. J Adv Res. 2023 Oct 6:S2090-1232(23)00299-0. J Adv Res. 2024 May 8:S2090-1232(24)00184-X. J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9. J Biol Chem. 2022 Aug 12;102374. J Biol Chem. 2024 Feb 1:105714. J Environ Sci. 2023 Feb 23. J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. J Hazard Mater. 2020 Jul 5;393:122440. J Hazard Mater. 2021 Apr 5;407:124387. J Hazard Mater. 2021 Jan 5;401:123341. JCI Insight. 2023 Nov 8;8(21):e167874. Life Sci. 2023 Jan 18;316:121404. Microvasc Res. 2023 Sep 28:151:104611. Nat Commun. 2023 Nov 27;14(1):7783. Nat Protoc. 2021 Jan;16(1):352-382. Nat Protoc. 2023 Feb 15. Nature. 2022 Jan;601(7894):600-605. Nature. 2022 Nov;611(7936):603-613. Nutrients. 2023 Feb 9;15(4):887. Patent. US20180263995A1. Patent. US20220062272A1. PLoS One. 2024 Feb 7;19(2):e0295030. Research Square Preprint. 2020 Aug 20;rs.3.rs-62758. Sci Adv. 2021 Sep 17;7(38):eabb5933. Sci Total Environ. 2023 Dec 30:913:169702. Science. 2020 Dec 4;370(6521):eaay2002. STAR Protoc. 16 December 2022, 101786. STAR Protoc. 2022 Sep 26;3(4):101720. STAR Protoc. 2023 Jul 9;4(3):102431. STAR Protoc. 2023 Nov 16;4(4):102683. Stem Cell Res. 2024 Sep 14:81:103562. Stem Cell Res. October 2021, 102544.
Smiles	O=C([C@@H]1CC[C@]([C@H](N)C)([H])CC1)NC2=CC=NC=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Y 27632, Y27632
Shipping condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Organoid; ROCK
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	247.342
Product Description	Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Isoform	ROCK1; ROCK2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10071-10mM-safety-datasheet.pdf